The startup develops recombinant proteins that enhance the body's innate immune response and repair immune cells, targeting conditions such as sepsis, cancer, and trauma. By providing pharmaceutical companies and healthcare providers with a novel platform, the company aims to improve patient outcomes across various therapeutic areas.
Funding
$270K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Sepsis, major surgery, trauma, and the immunosuppressive tumor microenvironment can cause immune cell dysfunction, leading to increased susceptibility to infection, poor wound healing, and reduced effectiveness of cancer immunotherapies. Current treatments often fail to adequately restore innate immune function, resulting in high mortality rates and suboptimal patient outcomes.
Solution
SurvivX is developing SUR-101, a recombinant protein-based technology platform of potent innate immunity boosters designed to revive dysfunctional innate immune cells. Inspired by a protein found in a tropical parasite that confers resistance to sepsis, SUR-101 modulates key immunological functions by activating toll-like receptors (TLRs) 2 and 4, along with the CD14 pathway. This approach aims to enhance the host's innate immune system, improving outcomes in conditions such as sepsis, trauma, major surgery, and as a neoadjuvant to boost the effectiveness of cancer immunotherapy.
Target Audience
The primary target audience includes pharmaceutical companies and healthcare providers focused on developing novel therapeutics for sepsis, trauma, major surgery, and cancer immunotherapy.
Features
- SUR-101, a lead compound derived from observational studies of filariasis-infected individuals, acts as a highly potent booster of the innate immune system.
- Demonstrated survival benefit in validated animal models of polymicrobial sepsis and influenza-A virus H1N1 infection.
- Designed to address immune suppression in later stages of sepsis, promoting a pro-inflammatory response to improve survival.
- Potential application as a neoadjuvant chemotherapy to restore T cell function within the immunosuppressive tumor microenvironment.
- Aims to enhance the efficacy of current immunotherapeutic approaches by activating both innate and adaptive immunity.
- Part of a family of patented immune boosters developed as a platform technology.